Title: Dual antiplatelet therapy in high-risk patients
Authors: Van de Werf, Frans # ×
Issue Date: Aug-2007
Publisher: Oxford univ press
Series Title: European heart journal supplements vol:9 issue:D pages:D3-D9
Abstract: The use of antiplatelet monotherapy as part of treatment regimens for high-risk patients with thrombotic disease results in significant reductions in ischaemic outcomes. Numerous studies have highlighted the benefits of antiptatelet monotherapy, including the 2002 meta-analysis by the Antiplatelet Trialists' Collaboration. Aspirin was the most commonly studied agent in this analysis and, while it remains the mainstay of antiplatelet therapy for reducing the risk of cardiovascular events, it is associated with significant residual cardiovascular risk. There is, however, a growing body of evidence demonstrating that combining aspirin with other antiplatelet agents with different mechanisms of action further improves long-term clinical outcomes both in stroke patients and in patients with acute coronary syndromes.
ISSN: 1520-765X
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Cardiology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science